Alexion Pharmaceuticals, Inc.
Treating seizure with recombinant alkaline phosphatase
Last updated:
Abstract:
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Status:
Grant
Type:
Utility
Filling date:
18 Oct 2019
Issue date:
18 Jan 2022